Pfizer Stock News

Pfizer announced on Wednesday that it has started clinical trials that could lead to Paxlovid being available for children ages six and up. Medical experts on Long Island said the pill being shown to be safe and effective for children could be an important step toward ending the pandemic.

Sandra Goudie said no to Pfizer and told Stuff she was waiting for Novavax. Now she says she won''t get that Covid vaccine either.

Pfizer-BioNTech is moving into the next stages of development for a version of its COVID-19 antiviral pill that will be safe for children younger than 12 years of age.

Paxlovid, Pfizer''s highly effective antiviral COVID-19 drug, has begun Phase 2 and 3 trials for children between the ages of six and 17 years old, the company announced.

Watch Video Drugmaker Pfizer is now testing an antiviral pill to treat COVID in younger children. The drug company announced Wednesday it has started a clinical trial for Paxlovid in kids ages 6 to 17. The FDA has already authorized this treatment for high-risk individuals ages 12 and older. Data from Pfizer''s trial in adults 18 and older found it to be 89% effective at preventing hospitalization and death. In order for the pill to work, patients need to take it within five days of showing COVID symptoms. Trial locations include Mississippi, South Carolina and Texas, according to clinicaltrials.gov .

Pfizer Inc (NYSE: PFE ) has initiated a Phase 2/3 EPIC-PEDS trial to evaluate Paxlovid (nirmatrelvir and ritonavir tablets) in COVID-19 pediatric patients . The trial will include non-hospitalized, symptomatic pediatric participants with a confirmed diagnosis of COVID-19 who are at risk of progression to severe disease. The Phase 2/3 trial has approximately 140 pediatric participants under 18 years of … Full story available on Benzinga.com

The company’s antiviral pill, Paxlovid, is currently authorized for high-risk patients aged 12 and up. This study will look at kids above age 6. Read more: https://www.forbes.com/sites/alexknapp/2022/03/09/pfizers-started-clinical-trials-for-its-covid-antiviral-in-kids/

Pfizer announced Wednesday it has begun phases 2 and 3 of its pediatric clinical trial for Paxlovid, its COVID-19 antiviral treatment.

Pfizer on Wednesday announced it has begun phase 2 and 3 stages of its study into the use of its antiviral COVID-19 treatment in young children.The oral COVID-19 treatment called PAXLOVID is currently one of two authorized SARS-…

Pfizer has started a Phase 2/3 study for its Paxlovid antiviral COVID-19 therapy for kids aged 6 to 17, the company said Wednesday.

Pfizer said on Wednesday it has begun a mid-to-late-stage study of its antiviral COVID-19 pill for non-hospitalized children aged 6-17 years who are at high risk of developing severe illness. Pfizer’s Paxlovid pill is authorized for emergency use in the United States for kids 12 years or older and high-risk adults. But there are no oral antiviral treatments for COVID-19 authorized in the United States for younger children. The drugmaker plans to enroll 140 children in the study across two groups of 6- to 17-year-olds, with one group including those at least 40 kilograms in weight and the other weighing between 20 kgs and 40 kgs. Pfizer’s COVID product sales to top $50bn this year, investors want more “Since the beginning of the pandemic, more than 11 million children under the age of 18 in the United States alone have tested positive for COVID-19, representing nearly 18% of reported cases and leading to more than 100,000 hospital admissions,” said Pfizer Chief Scientific Officer Mikael Dolsten.

Here''s a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus AbbVie Settles With Alvotech On Humira Biosimilar Patent Dispute AbbVie, Inc. (NYSE: ABBV ) and Alvotech announced a settlement agreement that gives Alvotech non-exclusive rights to market AVT01, a biosimilar to AbbVie''s Humira, in the U.S. The settlement gives Alvotech a license entry date into the U.S. of July 1, 2023. In February, the Food and Drug Administration accepted Alvotech''s biologic license application for ATV02, with the application including new data supporting interchangeability between ATV02 and Humira. AbbVie shares were adding 1.19% to $148.90 in premarket trading. NRx Pharma Founder & CEO Jonathan Javitt Retires NRx Pharmaceuticals, Inc. (NASDAQ: NRXP ) announced that Jonathan Javitt, the biopharma''s founder, has retired as chief executive officer, effective immediately. The board appointed Robert Besthof, Head of Operations and chief commercial officer, as Interim CEO.

Pfizer Inc. announced on Wednesday that it will start a "Phase 2/3 study" of its Paxlovid coronavirus treatment in children aged 6 to 17. The children will be divided into two groups separated by wei…

Pfizer (PFE) announced on Wednesday that it has started a Phase 2/3 study called EPIC-PEDS to evaluate its COVID-19 pill Paxlovid in non-hospitalized and symptomatic COVID-19 patients…

Pfizer has begun a Phase 2 and 3 clinical trial of its Covid-19 antiviral treatment, Paxlovid, in children ages 6 to 17, the company said Wednesday in a news release.